DPA International on MSN38m
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its ...
Anadolu Ajansi54m
BioNTech to buy Chinese biotech firm to boost oncology strategy
German drugmaker to use state-of-art antibody in tandem with advanced therapies to more effectively fight cancer, detect ...
Seeking Alpha on MSN46m
BioNTech to buy bispecific antibody developer Biotheus for up to $950M
BioNTech (BNTX) plans to initiate multiple registration trials in 2024 and 2025 that will evaluate BNT327/PM8002 in combination with chemotherapy for the treatment of small cell lung cancer, non-small ...
Finanznachrichten15m
Pulmatrix Inc.: Pulmatrix and Cullgen Announce Proposed Merger
Merger to create a Nasdaq-listed company focusing on targeted protein degradation technology with three degrader programs in or about to initiate Phase 1 clinical trials - two for the treatment of ...